Mercer Global Advisors Inc. ADV Purchases Shares of 15,000 SI-BONE, Inc. (NASDAQ:SIBN)

Mercer Global Advisors Inc. ADV acquired a new position in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 15,000 shares of the company's stock, valued at approximately $210,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Schonfeld Strategic Advisors LLC purchased a new position in shares of SI-BONE during the 4th quarter worth approximately $426,000. Northern Trust Corp raised its holdings in SI-BONE by 6.3% in the 4th quarter. Northern Trust Corp now owns 409,122 shares of the company's stock worth $5,736,000 after purchasing an additional 24,214 shares during the period. Aquatic Capital Management LLC increased its stake in shares of SI-BONE by 83.7% in the fourth quarter. Aquatic Capital Management LLC now owns 12,126 shares of the company's stock worth $170,000 after purchasing an additional 5,526 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in SI-BONE by 11.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 31,742 shares of the company's stock valued at $446,000 after buying an additional 3,318 shares in the last quarter. Finally, MetLife Investment Management LLC increased its position in SI-BONE by 17.6% in the fourth quarter. MetLife Investment Management LLC now owns 27,421 shares of the company's stock worth $384,000 after purchasing an additional 4,104 shares during the last quarter. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

SIBN has been the subject of several research reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price objective on shares of SI-BONE in a research report on Tuesday, May 6th. Needham & Company LLC reiterated a "buy" rating and issued a $24.00 price objective on shares of SI-BONE in a research report on Tuesday, May 6th. Finally, Truist Financial raised their price objective on SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a report on Tuesday, May 6th.

Insider Buying and Selling at SI-BONE

In other SI-BONE news, SVP Michael A. Pisetsky sold 3,128 shares of SI-BONE stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total value of $44,229.92. Following the sale, the senior vice president now directly owns 244,878 shares in the company, valued at approximately $3,462,574.92. The trade was a 1.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Anshul Maheshwari sold 4,937 shares of the business's stock in a transaction that occurred on Wednesday, May 7th. The stock was sold at an average price of $17.00, for a total value of $83,929.00. Following the transaction, the chief financial officer now directly owns 265,356 shares in the company, valued at approximately $4,511,052. This trade represents a 1.83% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 55,153 shares of company stock valued at $935,040 in the last ninety days. Company insiders own 4.00% of the company's stock.

SI-BONE Stock Up 1.3%

SIBN stock traded up $0.26 during trading on Tuesday, reaching $19.71. The stock had a trading volume of 300,623 shares, compared to its average volume of 374,819. SI-BONE, Inc. has a 1-year low of $11.70 and a 1-year high of $20.05. The firm has a fifty day moving average price of $14.92 and a 200 day moving average price of $15.08. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $839.94 million, a P/E ratio of -21.42 and a beta of 0.82.

SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.09. The business had revenue of $47.29 million during the quarter, compared to analyst estimates of $45.13 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. On average, equities analysts anticipate that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.